tbuckley/cabot-search huggingface dataset:
Prevalence of posttraumatic stress disorder in wounded Vietnam veterans
Authors: R K Pitman, B Altman, M L Macklin
Journal: American Journal of Psychiatry (1989)

Of 156 wounded Vietnam veterans evaluated for posttraumatic stress disorder (PTSD) by a questionnaire and a diagnostic interview in selected cases, 40% had a definite or probable lifetime diagnosis of PTSD. Of the 27 interviewed patients with lifetime PTSD, 81% currently met the PTSD criteria.
Clinical Treatment Decisions for Advanced Renal Cell Cancer
Authors: Toni K. Choueiri
Journal: Journal of the National Comprehensive Cancer Network (2013)

Seven targeted agents have improved the prognosis of advanced renal cell carcinoma (RCC), but none are effective in the post-nephrectomy adjuvant setting. Among the available first-line options for advanced RCC, sunitinib remains the most commonly used first-line therapy, but several studies suggest pazopanib may be better tolerated. Increasingly, choice of therapy may be driven by toxicity profiles. Cytoreductive nephrectomy remains important, even in the era of targeted therapies in selected patients.
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
Authors: H Wu, C Hu, A Wang, E L Weisberg, Y Chen, C-H Yun, W Wang, Y Liu, X Liu, B Tian, J Wang, Z Zhao, Y Liang, B Li, L Wang, B Wang, C Chen, S J Buhrlage, Z Qi, F Zou, A Nonami, Y Li, S M Fernandes, S Adamia, R M Stone, I A Galinsky, X Wang, G Yang, J D Griffin, J R Brown, M J Eck, J Liu, N S Gray, Q Liu
Journal: Leukemia (2015)
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
Authors: Bert Oosthuyse, Lieve Moons, Erik Storkebaum, Heike Beck, Dieter Nuyens, Koen Brusselmans, Jo Van Dorpe, Peter Hellings, Marchel Gorselink, Stéphane Heymans, Gregor Theilmeier, Mieke Dewerchin, Vincent Laudenbach, Patrick Vermylen, Harold Raat, Till Acker, Vicky Vleminckx, Ludo Van Den Bosch, Neil Cashman, Hajime Fujisawa, Maarten R. Drost, Raf Sciot, Frans Bruyninckx, Daniel J Hicklin, Can Ince, Pierre Gressens, Florea Lupu, Karl H. Plate, Wim Robberecht, Jean-Marc Herbert, Désiré Collen, Peter Carmeliet
Journal: Nature Genetics (2001)
Factors associated with bronchial hyperresponsiveness in Australian adults and children
Authors: JK Peat, CM Salome, AJ Woolcock
Journal: European Respiratory Journal (1992)

To accurately assess putative risk factors for bronchial hyperresponsiveness (BHR), we have used multivariate models to analyse data from 4,366 children living in four regions and from 878 adults. A standard protocol was used to measure bronchial responsiveness to histamine. The prevalence of BHR was high at 7-9 yrs (16-18%), decreased significantly at 11-14 yrs (7-8%), and then increased in adults (12-14%). Atopy was the most important risk factor for BHR at all ages. In children, parental asthma, early respiratory illness and being born in Australia also had a significant influence, and eating fish more than once a week had a protective effect. No effect of parental smoking, gender or race was found. In adults, BHR was associated with being female and with smoking history. It appears that many factors have a significant influence on the presence of BHR, with environmental factors, particularly atopy, birthplace and diet, being the most important.
Abstract P288: Exposure To Psychological And Physical Challenges Immediately Prior To Myocardial Infarction And Increased 10-year Mortality
Authors: Loes Smeijers, Elizabeth Mostofsky, Willem J Kop, Murray A Mittelman
Journal: Circulation (2014)

Objective: To examine the association between exposure to psychological (anger, anxiety) and physical (high activity levels, coffee consumption) challenge immediately prior to myocardial infarction (MI) as risk indicator of mortality at 10-year follow-up. Methods: Participants of the Determinants of Myocardial Infarction Onset Study (N=2176, mean age 60.1±12.5 yrs, 29.2% women) were interviewed to assess exposure to several potential triggers immediately prior to MI, including anger, anxiety, physical activity and coffee. All-cause mortality was assessed using the National Death Index for 10 years follow-up. We constructed Cox proportional hazards models with 95% confidence intervals to examine the relationship between exposure to these potential triggers in the 2 hours prior to MI onset and the rate of all-cause mortality, adjusting for demographic and clinical characteristics. Results: Exposure to anger, anxiety, physical activity or coffee consumption prior to MI was associated with a 30% higher mortality rate over 10 years (HR=1.30, 95%CI=1.06-1.59, p =0.011) compared to patients who were not exposed to any of these potential triggers. This association was stronger for the first 3 years of follow-up (HR=1.59, 95%CI=1.16-2.19, p =0.004) and weaker for years 3 to 10 (HR=1.14, 95%CI=0.88-1.48, p =0.32). In separate analyses for each exposure, there was a higher mortality rate associated with anxiety (HR=1.44, 95%CI=1.09-1.91, p =0.010) and a suggestion of a higher rate for anger (HR=1.33, 95%CI=0.97-1.81, p =0.075), but no association for physical activity or coffee consumption. Sensitivity analyses showed stronger associations for women than men, and patients aged 65 and older compared to younger patients. Discussion: MI following episodes of anger, anxiety, physical activity or coffee consumption is associated with higher all-cause mortality in the following 10 years. This association was strongest for anxiety and slightly lower for anger but there was no evidence of a higher mortality rate among MI patients reporting physical activity or coffee consumption immediately prior to MI.
Stem Cell Growth and Production of Colony-Stimulating Factor in Rauscher Virus-Infected CBA/J Mice2
Authors: R. G. Iturriza, H. J. Seidel
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Stem Cell Growth and Production of Colony-Stimulating Factor in Rauscher Virus-Infected CBA/J Mice Get access R. G. Iturriza, R. G. Iturriza Search for other works by this author on: Oxford Academic PubMed Google Scholar H. J. Seidel H. J. Seidel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 2, August 1974, Pages 487–492, https://doi.org/10.1093/jnci/53.2.487 Published: 01 August 1974 Article history Received: 04 February 1974 Accepted: 19 April 1974 Published: 01 August 1974
Interferon gamma boosts the nucleotide oligomerization domain 2-mediated signaling pathway in human dendritic cells in an X-linked inhibitor of apoptosis protein and mammalian target of rapamycin-dependent manner
Authors: Tünde Fekete, Gabor Koncz, Brigitta Szabo, Andrea Gregus, Eva Rajnavölgyi
Journal: Cellular and Molecular Immunology (2015)
Quality-of-Life Measurement in Advanced Cancer: Assessing the Individual
Authors: Dympna Waldron, Ciaran A. O'Boyle, Michael Kearney, Michael Moriarty, Desmond Carney
Journal: Journal of Clinical Oncology (1999)

PURPOSE: Despite the increasing importance of assessing quality of life (QoL) in patients with advanced cancer, relatively little is known about individual patient's perceptions of the issues contributing to their QoL. The Schedule for the Evaluation of Individual Quality of Life (SEIQoL) and the shorter SEIQoL–Direct Weighting (SEIQoL-DW) assess individualized QoL using a semistructured interview technique. Here we report findings from the first administration of the SEIQoL and SEIQoL-DW to patients with advanced incurable cancer. PATIENTS AND METHODS: QoL was assessed on a single occasion using the SEIQoL and SEIQoL-DW in 80 patients with advanced incurable cancer. RESULTS: All patients were able to complete the SEIQoL-DW, and 78% completed the SEIQoL. Of a possible score of 100, the median QoL global score was as follows: SEIQoL, 61 (range, 24 to 94); SEIQoL-DW, 60.5 (range, 6 to 95). Psychometric data for SEIQoL indicated very high levels of internal consistency (median r = .90) and internal validity (median R 2 = 0.88). Patients' judgments of their QoL were unique to the individual. Family concerns were almost universally rated as more important than health, the difference being significant when measured using the SEIQoL-DW (P = .002). CONCLUSION: Patients with advanced incurable cancer were very good judges of their QoL, and many patients rated their QoL as good. Judgments were highly individual, with very high levels of consistency and validity. The primacy given to health in many QoL questionnaires may be questioned in this population. The implications of these findings are discussed with regard to clinical assessment and advance directives.
Preclinical Screening for Drugs Effective Against 5-Fluorouracil-Resistant Cells With a Murine L5178Y Cell Line In Vitro
Authors: B T Hill
Journal: JNCI Journal of the National Cancer Institute (1983)

A subline of L5178Y cells has been established in vitro that exhibits a fiftyfold order of resistance to 5-fluorouracil (FUra) as compared to that of the parent line. The cytotoxic effects of 24-hour exposures to 23 antitumor drugs and to radiation were compared in the two cell lines. Four patterns of response were identified: 1) Only two drugs, mitomycin C and adriamycin, proved significantly more cytotoxic to FUra-resistant cells. 2) Four other drugs—anguidine, 4′-(9-acridinylammo)-methanesulfon-m-anisidide, melphalan, and quelamycin—showed marginal superiority against resistant cells. 3) X-radiation and the majority of drugs tested—including 5-azacytidine, 1,3-bis(2-chloroethyl)-1-nitrosourea, cisplatin, bleomycin, dibromodulcitol, razoxane, hydroxyurea, methotrexate, teniposide, etoposide, and three experimental agents, metoprine, spirogermanium HCI, and ellipticinum—proved equally cytotoxic to both cell lines. 4) Cross-resistance with FUra was exhibited with vincristine, vindesine, pyrazofurin, and indicine-N-oxide. This experimental system provides a simple method of testing agents for activity against FUra-resistant cells before phase I clinical studies.
Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.
Authors: M P Gawaz, G Dobos, M Späth, P Schollmeyer, H J Gurland, S K Mujais
Journal: Journal of the American Society of Nephrology (1994)

Impaired platelet function and a bleeding tendency are well-recognized complications of chronic renal failure. Because the fibrinogen receptor GPIIb-IIIa plays a central role in platelet aggregation and adhesion to the subendothelium, it was reasoned that a defect in this receptor may underlie the impaired platelet function in uremia. To test this hypothesis, the function of this receptor in the platelets of 11 uremic patients was studied. Aggregation studies were performed with flow cytometric techniques with anti-GPIIb-IIIa conformation-specific monoclonal antibodies (mAb) (anti-LIBS1 and anti-PMI-1). Antifibrinogen and antithrombospondin mAb were used to characterize fibrinogen binding to GPIIb-IIIa and the release of alpha-granules, respectively. Platelets from patients with chronic renal failure showed significantly decreased binding of conformation-dependent anti-LIBS1 mAb after ADP, phorbol myristate acetate, or RGD-peptide stimulation compared with normal controls, suggesting a defect related to the ability of the fibrinogen receptor to undergo a conformational change. Moreover, antifibrinogen and antithrombospondin binding to activated platelets were reduced in uremic patients, implying impairment of both ligand-binding and alpha-granule release. Hemodialysis partially restored GPIIb-IIIa function, which may account for the observed effects of this therapy in restoring platelet aggregation. These findings indicate that platelets of patients with chronic renal failure reveal an aggregation defect at least partially due to an intrinsic GPIIb-IIIa dysfunction and the presence of a putative uremic toxin that inhibits fibrinogen binding to GPIIb-IIIa.
Cutaneous T-Cell Lymphoma in Sub-Saharan Africa
Authors: Matthew Ulrickson, Fred Okuku, Victoria Walusansa, Oliver Press, Sam Kalungi, David Wu, Fred Kambugu, Corey Casper, Jackson Orem
Journal: Journal of the National Comprehensive Cancer Network (2013)

The incidence and economic burden of cancer in sub-Saharan Africa is increasing, and innovative strategies are needed to improve prevention and care in this population. This article uses a case of cutaneous T-cell lymphoma in Uganda to propose guidelines for the diagnosis and treatment of this disease in resource-limited settings. These guidelines were developed from the consensus opinion of specialists at the Uganda Cancer Institute and Fred Hutchinson Cancer Research Center as part of an established collaboration. Areas for future investigation that can improve the care of patients in this region are identified.
Serologic Evidence for a Simian-Virus-40-Like Infection of Man&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Keerti V. Shah, Fred R. McCrumb, Richard W. Daniel, Harvey L. Ozer
Journal: JNCI Journal of the National Cancer Institute (1972)

Sera from 4 groups of donors were tested for the presence of simian virus 40 (SV40)-reacting antibodies. Neutralizing antibodies were found in about 20% of the sera of Maryland children born between 1955 and 1957. This group had a high risk of having received SV40-contaminated Salk poliomyelitis vaccine. SV40-neutralizing antibodies were also found in 9 (3.2%) sera of Maryland children born during or after 1964. Since 1961, vaccines were required to be free of SV40; thus it is unlikely that these children received SV40 in contaminated vaccines. Furthermore, SV40-reacting antibodies were detected in 4 (2%) sera from collections made in 1951 and 1954, before monkey kidney vaccines came into general use. The validity of the results from neutralization tests was confirmed by indirect immunofluorescence and radioisotope precipitation tests. The occurrence of SV40-reacting antibodies in sera of young Maryland children and in sera collected in the early 1950's strongly suggests the existence of an SV40-related infection of man.
Age-related increase in expression of TGF-beta1 in the rat kidney
Authors: M P Ruiz-Torres, R J Bosch, F O'Valle, R G Del Moral, C Ramírez, M Masseroli, C Pérez-Caballero, M C Iglesias, M Rodríguez-Puyol, D Rodríguez-Puyol
Journal: Journal of the American Society of Nephrology (1998)

In the kidney, aging is characterized by the development of structural changes, including glomerulosclerosis and interstitial fibrosis. Transforming growth factor-beta1 (TGF-beta1) is known to play a critical role in the genesis of these alterations in pathologic conditions. The present experiments were designed to test the hypothesis that TGF-beta1 may be involved in the development of age-related histopathologic changes in rat kidney, and that captopril, an angiotensin-converting enzyme inhibitor, may influence the progression of glomerular and interstitial lesions. In this study, 3-, 18-, 24-, and 30-mo-old rats were examined, and an age-related increase in urinary protein excretion was found; plasma creatinine and systolic BP did not change. Significant structural changes, including glomerular sclerosis and interstitial fibrosis, were found in the group of aged rats (24- and 30-mo-old). Immunostaining for TGF-beta in the renal cortex interstitium was increased in the group of 24-mo-old rats, with a parallel increase in TGF-beta1 mRNA expression, measured with reverse-transcription PCR. Captopril-treated animals showed a statistically significant decrease in urinary protein excretion but no significant changes in BP. Moreover, captopril reduced the extent of interstitial fibrosis, but did not affect the degree of glomerulosclerosis. A significant inhibition of TGF-beta1 mRNA expression was observed in the captopril-treated animals. These findings suggest that TGF-beta1 may act as a fibrogenic growth factor that could be responsible, at least partially, for the renal interstitial fibrosis associated with aging. Treatment with captopril might delay the progression of these lesions.
Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia?
Authors: Caroline Gouder, Marija Agius, Donia Gamoudi, Nadia Gamoudi, David Farrugia, Michael Borg, Josef Micallef
Journal: European Respiratory Journal (2014)

Aim :To assess whether established warfarin treatment affects outcome in hospitalised patients with community-acquired pneumonia(CAP).

Methodology:This retrospective study included adults with confirmed CAP clinically and on CXR. A total of 30 patients on warfarin were compared to 30 controls (not on warfarin). These were matched for time of presentation, age (+/-2 years), gender and co-morbidities. The co-morbidities included diabetes mellitus, ischaemic heart disease, congestive cardiac failure, chronic lung disease, chronic kidney and liver disease and immunosuppression. Outcome was assessed in terms of CURB65 score, complications (empyema, lung abscess, pleural effusion, respiratory failure, sepsis), length of hospital stay and 30-day mortality.

Results:A total of 60 CAP patients (30 on warfarin, 30 controls) were included with a mean age of 78.4+/-8.7 in the warfarin group and 78.9+/-8.4 in the control group. Patients on anticoagulation had higher CURB65 scores (3 to 5) on admission at 27% compared to the 17% of the control group. The patients on warfarin had less complications (10 warfarin versus 17 control), decreased hospital stay (median 6 days versus 7 days, p =0.84), decreased mortality as in-patients and at 30 days (7 on warfarin versus 11 controls).

Conclusion:Hospitalised CAP patients on established home warfarin treatment, despite presenting with more severe pneumonia on CURB65 score, had less pneumonia complications, decreased hospital stay and 30-day mortality. A large randomised control trial may help establish whether inpatient anticoagulation will help improve outcome in hospitalised patients with this common respiratory condition.
Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening
Authors: H. Hu, C. Harmer, S. Anuj, C.E. Wainwright, J. Manos, J. Cheney, C. Harbour, I. Zablotska, L. Turnbull, C.B. Whitchurch, K. Grimwood, B. Rose
Journal: Clinical Microbiology and Infection (2012)
In Vitro Studies on the Cell-Mediated Immune Response to Human Brain Tumors. I. Requirement for Third-Party Stimulator Lymphocytes in the Induction of Cell-Mediated Cytotoxic Responses to Allogeneic Cultured Gliomas&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: M K Gately, M Glaser, S J Dick, R W Mettetal, P L Kornblith
Journal: JNCI Journal of the National Cancer Institute (1982)

For study of those properties of human gliomas that might contribute to their ability to escape cell-mediated immune attack, cultured human glioma cells were examined for their ability to elicit allogeneic cytolytic lymphocyte responses in vitro. Of 9 glioma lines, 5 were unable to elicit allogeneic cytolytic lymphocyte responses in mixed lymphocyte-tumor cultures although the concentration of stimulating glioma cells was varied over a fortyfold range. However, lymphocytes specifically cytolytic for 4 of the nonstimulatory lines could be generated if irradiated, third-party stimulator lymphocytes were added to cultures containing responder lymphocytes and glioma cells. The specific cytolytic lymphocytes produced in these cultures were inactivated by treatment with the monoclonal anti- T-cell antibody OKT3 plus complement and were thus identified as T-cells. However, nonspecific, non-T-Iytic effectors were also generated. The results of these experiments demonstrated that certain cultured gliomas possessed a defect in immunogenicity that can be overcome by “help” from an allogeneic mixed lymphocyte reaction. The possible nature of this help and the potential implications of these results for the immunotherapy of human gliomas are discussed.
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation
Authors: Daniel Pilsgaard Henriksen, Morten Rix Hansen, Per Damkier
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Ultrasound-guided hip joint injections are more accurate than landmark-guided injections: a systematic review and meta-analysis
Authors: Shane Hoeber, Abdel-Rahman Aly, Nigel Ashworth, Sathish Rajasekaran
Journal: British Journal of Sports Medicine (2015)

Aim To compare the accuracy of ultrasound (US)-guided versus landmark-guided hip joint injections. Methods PubMed, Medline and Cochrane libraries were searched up to 31 July 2014. Two independent authors selected studies assessing accuracy of intra-articular hip injections based on predetermined inclusion and exclusion criteria. Selected papers were then evaluated for quality and a meta-analysis of accuracy was performed using random effects models. Results 4 US-guided (136 hip injections) and 5 landmark-guided (295 hip injections) studies were reviewed. The weighted means for US-guided and landmark-guided hip injection accuracies were 100% (95% CI 98% to 100%) and 72% (95% CI 56% to 85%), respectively. US-guided hip injection accuracy was significantly higher than landmark-guided accuracy (p&lt;0.0001). Summary This is the first systematic review and meta-analysis of the accuracy of US-guided versus landmark-guided hip joint injections that has revealed that US-guided injections are significantly more accurate than those that are landmark guided. Future studies should compare US with fluoroscopic-guided hip joint injections for accuracy, efficacy, safety profile, cost-effectiveness and patient satisfaction.
Outbreak of vancomycin-resistant Enterococcus spp. in an Italian general intensive care unit
Authors: M. Peta, E. Carretto, D. Barbarini, A. Zamperoni, L. Carnevale, L. Perversi, M. Pagani, M.G. Bonora, R. Fontana, P. Marone, M. Langer
Journal: Clinical Microbiology and Infection (2006)